

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Reproductive Health Science Limited
ABN	84 010 126 708

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Brookes
Date of last notice	13 October 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	1) Dr David Brookes and Mrs Elisabeth Brookes ATF Dr DL Brookes Personal Super Fund 2) Mrs Elisabeth Brookes ATF Dahlbrook Family Trust
Date of change	31 December 2016
No. of securities held prior to change	<u>Direct</u> 455,158 Ordinary Fully Paid Shares <u>Indirect</u> 1) <ul style="list-style-type: none">781,616 Ordinary Fully Paid Shares1,250,000 Unlisted Options exercisable at \$0.318, expiring 31 December 2016.1,400,000 Unlisted Options exercisable at \$0.208, expiring 31 May 2020. 2) 618,000 Ordinary Fully Paid Shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Ordinary Fully Paid Shares Unlisted options
Number acquired	Nil
Number disposed	Expiry of 1,250,000 Unlisted Options exercisable at \$0.318 (expired 31 December 2016).
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A
No. of securities held after change	<u>Direct</u> <ul style="list-style-type: none"> 455,158 Ordinary Fully Paid Shares <u>Indirect</u> <ol style="list-style-type: none"> <ul style="list-style-type: none"> 781,616 Ordinary Fully Paid Shares 1,400,000 Unlisted Options exercisable at \$0.208, expiring 31 May 2020. <ul style="list-style-type: none"> 618,000 Ordinary Fully Paid Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of unlisted options.

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Not applicable
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

⁺ See chapter 19 for defined terms.